Outcomes of Functional Substrate Mapping of Ventricular Tachycardia
NCT ID: NCT05708131
Last Updated: 2024-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
70 participants
OBSERVATIONAL
2022-07-13
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Late Potentials and Ablation Index in Ventricular Tachycardia Ablation
NCT03437408
Functional Substrate-Only Guided VT Ablation
NCT06464315
Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators
NCT01557842
Substrate Modification in Stable Ventricular Tachycardia in Addition to Implantable Cardioverter Defibrillator (ICD) Therapy
NCT00919373
Ventricular Tachycardia Ablation in LVAD Patients
NCT06063811
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A: ≥3 episodes of VT treated with anti-tachycardia pacing (ATP), at least one of which is symptomatic.
B: ≥1 appropriate ICD shock. C: ≥3 VT episodes within 24 hr. D: Sustained VT below the detection rate of the ICD.
Exclusion Criteria
* Renal failure (CrCl \< 15 mL/min)
* NYHA IV or CCS IV angina
* STEMI within 1 month
* CABG within 3 months
* PCI within 1 month
* Pregnant
* Life expectancy \< 1 year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Mid and South Essex NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Neil Srinvasan, MBBS
Role: PRINCIPAL_INVESTIGATOR
Mid and South Essex NHS FT
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Onassis Cardiac Surgery Center
Athens, , Greece
Virgen de las Nieves University Hospital
Granada, , Spain
Arrhythmia Unit, University Hospital Ramón y Cajal
Madrid, , Spain
Basildon University Hospital
Basildon, , United Kingdom
Royal Sussex County Hospital
Brighton, , United Kingdom
Royal Brompton & Harefield hospital
London, , United Kingdom
St Bartholomew's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pasquale Santangeli
Role: primary
Konstantinos G Vlachos
Role: primary
Pablo J Sánchez-Millán
Role: primary
Javier Moreno
Role: primary
John Silberbauer
Role: primary
Chen Zhong
Role: primary
Ross Hunter
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
315453
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.